Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Iberhospitex S A has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, Celeste A Roney, and is situated within a distinct art unit. This individual is the busiest examiner for the company, overseeing the pending workload.
The company's current prosecution activity is focused on the matter within Biotechnology & Pharmaceuticals. This pending office action is being reviewed by Celeste A Roney, which centralizes the legal risk and strategy for this portfolio. This official is the sole person managing the legal matters currently active.
The involvement of a distinct art unit suggests that the pending office action relates to a specific technical niche within the broader field. Because there is only the pending office action, the company's immediate patent goals are tied to the decisions of the examiner. The current review will determine the outcome for the prosecution effort in this specific case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RONEY, CELESTE A | 1 | 63.0% | +17.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18292107 | COMPOSITIONS FOR EMBOLIZATION | RONEY, CELESTE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18292107 | COMPOSITIONS FOR EMBOLIZATION | RONEY, CELESTE A | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18292107 | COMPOSITIONS FOR EMBOLIZATION | RONEY, CELESTE A | 1612 | §103§112 | Non-Final OA | — | Pending | Jan 25, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIberhospitex S A has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Celeste A Roney has the most, with 1 of Iberhospitex S A's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
